Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Immatics N.V.

Market Cap 1.28B 1.11B 1.02B 955M 1.79B 122B 1.82B 12.05B 4.7B 59.31B 4.81B 4.71B 205B P/E Ratio 2026 *
-4.58x
P/E Ratio 2027 * -4.98x
Enterprise Value 989M 855M 787M 737M 1.38B 94.04B 1.4B 9.3B 3.63B 45.78B 3.71B 3.63B 158B EV / Sales 2026 *
21.5x
EV / Sales 2027 * 18.5x
Free-Float
74.82%
Yield 2026 *
-
Yield 2027 * -
1 day+3.53%
1 week-4.19%
Current month-18.51%
1 month-13.07%
3 months+1.52%
6 months-6.57%
Current year-10.67%
1 week 8.76
Extreme 8.76
10.04
1 month 8.76
Extreme 8.76
11.86
Current year 8.55
Extreme 8.55
11.94
1 year 5.05
Extreme 5.05
12.41
3 years 3.3
Extreme 3.3
13.77
5 years 3.3
Extreme 3.3
16.3
10 years 0
Extreme 0
18.42
Manager TitleAgeSince
Chief Executive Officer 51 2018-12-31
Director of Finance/CFO 57 2025-09-30
Chief Tech/Sci/R&D Officer - 2024-12-31
Director TitleAgeSince
Director/Board Member 51 2020-06-30
Chairman 70 2012-09-30
Director/Board Member 72 2020-06-30
Date Insider Type Main position Quantity % Market Cap.
Mar. 17Other

Director

171,500 0.1279%
Mar. 17Other

Chief Technology Officer

1,164,079 0.8683%
Mar. 17Other

Director

171,500 0.1279%
Change 5-day change 1-year change 3-year change Capi.($)
+3.53%-4.19%+53.27%-22.03% 1.28B
+1.03%+2.30%+55.91%+114.22% 56.42B
+2.72%+3.26%+46.05%+44.91% 44.54B
+1.12%+2.79%-15.04%-21.68% 22.9B
+1.17%+3.85%-0.89%+403.86% 21.21B
+3.81%-5.07%+11.00%-30.62% 16.4B
+0.15%+2.24%+9.32%-39.30% 15.4B
-0.69%+0.82%+27.75%+176.72% 13.35B
+5.27%+5.54%+19.65% - 12.36B
+1.61%+1.28%+95.75%+205.26% 11.15B
Average +1.97%+1.46%+30.28%+92.37% 21.5B
Weighted average by Cap. +1.73%+2.33%+32.16%+98.83%

Financials

2026 *2027 *
Net sales 45.94M 39.67M 36.56M 34.22M 64.13M 4.37B 65.13M 432M 168M 2.13B 172M 169M 7.36B 50.66M 43.76M 40.32M 37.74M 70.73M 4.82B 71.83M 476M 186M 2.34B 190M 186M 8.12B
Net income -279M -241M -222M -208M -390M -26.55B -396M -2.62B -1.02B -12.92B -1.05B -1.03B -44.74B -282M -243M -224M -210M -393M -26.78B -399M -2.65B -1.03B -13.03B -1.06B -1.03B -45.13B
Net Debt -293M -253M -233M -218M -408M -27.81B -415M -2.75B -1.07B -13.54B -1.1B -1.07B -46.87B -346M -299M -275M -258M -483M -32.89B -491M -3.25B -1.27B -16.01B -1.3B -1.27B -55.42B
Logo Immatics N.V.
Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
Employees
678
Date Price Change Volume
26-06-12 9.380 $ +3.53% 376,663
26-06-11 9.060 $ +2.14% 236,577
26-06-10 8.870 $ -3.17% 360,831
26-06-09 9.160 $ -0.65% 596,129
26-06-08 9.220 $ -5.82% 339,686
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
9.380USD
Average target price
18.78USD
Spread / Average Target
+100.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMTX Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!